Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q2 2025 · 10-Q
Revenue—
Net Income-$659.94K-$659.94KN/M vs Q2 2024 EPS Diluted$0.00$0.00— vs Q2 2024 Operating Income-$695,773N/M Operating Cash Flowderived-$583,991N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
ended Jun 30, 2025 · filed Aug 13, 2025 · 44 d after period end